Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, Régis Bataille, Meral Beksaç et al.|Leukemia|2011Cited by 721
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Α. Dimopoulos, Robert A. Kyle, Jean-Paul Fermand et al.|Blood|2011Cited by 450
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Simon J. Harrison, Asher Chanan‐Khan et al.|Blood|2017Cited by 271
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.William G. Wierda, Hema Sundar, John C. Byrd et al.|PubMed|2020Cited by 143
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G. Wierda, Hema Sundar, John C. Byrd et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 94